Method Article

Retinal Pathophysiological Evaluation in a Rat Model

DOI:

10.3791/63111

⸱

May 6th, 2022

 , 
1Translational Pharmaceutics Research Laboratory (TPRL), Department of Pharmacy, Birla Institute of Technology & Science — Pilani, Hyderabad Campus

In This Article

Summary

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Diabetic retinopathy is one of the leading causes of blindness. Histology, blood-retinal barrier breakdown assay, and fluorescence angiography are valuable techniques to understand the pathophysiology of the retina, which could further enhance the efficient drug screening against diabetic retinopathy.

Abstract

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

A posterior segment eye disease like diabetic retinopathy alters the physiology of the retina. Diabetic retinopathy is characterized by a retinal detachment, breakdown of the blood-retinal barrier (BRB), and retinal angiogenesis. An in vivo rat model is a valuable experimental tool to examine the changes in the structure and function of the retina. We propose three different experimental techniques in the rat model to identify morphological changes of retinal cells, retinal vasculature, and compromised BRB. Retinal histology is used to study the morphology of various retinal cells. Also, quantitative measurement is performed by retinal cell count and thickness measurement of different retinal layers. A BRB breakdown assay is used to determine the leakage of extraocular proteins from the plasma to vitreous tissue due to the breakdown of BRB. Fluorescence angiography is used to study angiogenesis and leakage of blood vessels by visualizing retinal vasculature using FITC-dextran dye.

Introduction

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Diabetic retinopathy (DR) is one of the most complex secondary complications of diabetes mellitus. It is also the leading cause of preventable blindness in the working-age population worldwide. In a recent meta-analysis of 32.4 million blind people, 830,000 (2.6%) people were blind due to DR1. The proportion of vision loss attributed to diabetes ranked seventh in 2015 at 1.06% (0.15-2.38) globally2,3.

Diabetic retinopathy is diagnosed by vascular abnormalities in the posterior ocular tissues. Clinically, it is divided into two stages - Non-Proliferative DR (NPDR) and Proliferative DR (PDR), based on the vascularization in the retina. Hyperglycemia is considered the potent regulator of DR as it implicates several pathways involved in neurodegeneration4,5, inflammation6,7, and microvasculature8 in the retina. Multiple metabolic complications induced due to hyperglycemia include the accumulation of advanced glycation end products (AGEs), polyol pathway, hexosamine pathway, and protein kinase-C pathway. These pathways are responsible for cell proliferation (endothelial cells), migration (pericytes), and apoptosis (neural retinal cells, pericytes, and endothelial cells) based on different stages of diabetic retinopathy. These metabolic alterations can lead to physiological changes such as retinal detachment, loss of retinal cells, breakdown of the blood-retinal barrier (BRB), aneurysms, and angiogenesis9.

Streptozotocin (STZ) induced type-1 diabetes is a well-established and well-accepted practice in rats for evaluating diabetes pathogenesis and its complications. Diabetogenic effects of STZ are due to selective destruction of pancreatic islet β-cells10. As a result, the animals will undergo insulin deficiency, hyperglycemia, polydipsia, and polyuria, all of which are characteristic of human type-1 diabetes mellitus11. For severe diabetes induction, STZ is administered at 40-65 mg/kg body weight intravenously or intraperitoneally during adulthood. After approximately 72 h, these animals present blood glucose levels greater than 250 mg/dL10,12.

To understand the physiological alterations of the retina due to neurodegeneration, inflammation, and angiogenesis, different techniques should be optimized in experimental animal models. Structural and functional changes in retinal cells and retinal vessels can be studied by various techniques such as histology, BRB breakdown assay, and fluorescence angiography.

Histology involves the study of the anatomy of cells, tissues, and organs at a microscopic level. It establishes a correlation between the structure and function of cells/tissue. Several steps are performed to visualize and identify the microscopic alterations in tissue structure, thereby comparing healthy and diseased counterparts13. Hence, it is essential to standardize each step of histology meticulously. Various steps involved in retinal histology are fixation of the specimen, trimming the specimen, dehydration, clearing, impregnation with paraffin, paraffin embedding, sectioning, and staining (Hematoxylin and Eosin staining)13,14.

In a healthy retina, the transport of molecules across the retina is controlled by BRB, composed of endothelial cells and pericytes on the inner side, and retinal pigment epithelial cells on the outer side. However, inner BRB endothelial cells and pericytes start degenerating during the diseased condition, and BRB is also compromised15. Due to this BRB breakdown, many low molecular weight molecules leak into vitreous and retinal tissue16. As the disease progresses, many other protein molecules (low and high molecular weight) also leak into vitreous and retinal tissue due to homeostasis disturbance17. It leads to various other complications and ultimately macular edema and blindness. Hence, quantifying the protein levels in the vitreous and comparing healthy and diabetic states measures compromised BRB.

Fluorescence angiography is a technique used to study blood circulation of the retina and choroid using fluorescent dye. It is used to visualize vasculature of the retina and choroid by injecting fluorescein dye via intravenous route or cardiac injection18. Once the dye is injected, it first reaches the retinal arteries, followed by retinal veins. This circulation of dye is usually completed within 5 to 10 min from the injection of dye19. It is an important technique to diagnose various posterior segment ocular diseases, including diabetic retinopathy and choroidal neovascularization20. It helps to detect major and minor vasculature changes in normal and diseased conditions.

Access restricted. Please log in or start a trial to view this content.

Protocol

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This protocol follows all the animal care guidelines provided by Institutional Animal Ethics Committee, BITS-Pilani, Hyderabad campus.

1. Retinal histology

  1. Enucleation and fixation of the eye
    1. Euthanize a 2 to 3-month-old diabetic Wistar male rat along with the age-matched control (14 to 15 weeks old) using a high dose of pentobarbital (150 mg/kg) injected through the intraperitoneal route. No detectable heartbeat confirms the death within 2-5 min.
    2. Enucleate the eye by making incisions using a scalpel blade on the nasal and temporal regions of the eye. Then cut along its edges using forceps and micro scissors to remove the eye from the orbital socket.
      NOTE: Before sacrificing rats, keep the fixative solutions ready.
      CAUTION: Formaldehyde irritates the skin, eye, nose, and respiratory tract. It can also cause cancer as it is a potent skin sensitizer. Wear gloves and handle it under the hood21.
    3. Wash the eye thoroughly with 10 mL of phosphate-buffered saline (PBS) solution in a Petri dish to remove blood. Remove the excess fat surrounding the eye for easy penetration of the fixative solution.
    4. Immediately place the eye in 5 mL of fixative solution with the help of forceps, and make sure it is not stuck to walls of glass vials. Stir gently for a few seconds and replace the cap with proper labeling. Incubate eye in fixative solution for 24 to 48 h in dark conditions at room temperature.
  2. Trimming of tissue
    1. After fixation, remove the eye from the fixative solution, wash with 10 mL of PBS, and place it in a Petri dish containing 10 mL of PBS chilled at 4 °C.
    2. Using micro forceps, hold the eye with the optic nerve and make a nick at pars plana with the help of micro scissors. Cut through the entire margin of the cornea to separate the anterior cup of an eye. Using forceps, pick the lens gently, discard it, and cut the optic nerve.
    3. Using curved micro scissors, make a longitudinal section of the posterior eyecup, passing through the optic disc dividing it into two halves. Place it in the base of the cassette and close the lid properly without any disturbance to the tissue. Label the cassettes with the tissue sample name and date.
  3. Dehydration, clearing, and paraffin impregnation of tissue
    1. Dehydrate the trimmed tissue by gradual transfer in 80 mL of 50%, 70%, 90%, and 100% ethanol. While transferring the cassettes from one concentration to another, make sure to dab them on clean tissue paper to minimize contamination.
      NOTE: Allow the tissue to stand in each transfer for 30 min (twice). The total time consumed for this step is approximately 4 h.
    2. Upon dehydration, transfer the cassettes into 80 mL of xylene for 30 min (twice) to replace the ethanol with xylene.
      NOTE: After incubation with xylene, the tissue becomes translucent.
      CAUTION: Xylene is an aromatic compound with a benzene ring. It irritates the eye and mucous membrane and may also cause depressions.
    3. Finally, impregnate the tissue with pre-heated paraffin at 60 °C to replace xylene in the tissue. Dab the cassettes several times on tissue paper to minimize the xylene content and place in 200 mL of paraffin (liquid at 60 °C) for 2 h (1 h x 2).
      ​CAUTION: Avoid inhaling melted paraffin, as it produces tiny lipid droplets which may cause respiratory discomfort.
  4. Paraffin embedding
    1. Turn on the paraffin embedding machine at least 1 h before use to melt the paraffin and for the stations to reach desired temperatures. Fill a steel mold with melted paraffin wax by placing it on a hot surface, then remove one cassette at a time from the paraffin container.
    2. Move the steel mold from a hot to a cold surface (4 °C). At this point, the wax in the mold will start to solidify. Before it solidifies completely, place the tissue in wax with the help of forceps and orient the tissue so that the optic disc portion of the posterior cup is facing the base of the mold.
      NOTE: Ensure that the tissue does not move and keep its desired orientation. If not, put the mold back onto the warm work surface until the whole paraffin liquefies, then start again with step 1.4.2.
    3. As the wax in the mold starts solidifying, immediately place the cassette base on top of the mold. Carefully fill the mold with paraffin above the upper edge of the cassette and slowly transfer it to a cold surface (near -20 °C) for rapid solidification. Until it solidifies, repeat the process with other cassettes from step 1.4.2.
    4. Once all the molds are solidified, separate the steel mold from the cassette. If it is hard, wait a bit longer and try again (do not remove it forcefully). Separation becomes easier upon complete solidification. Now the cassette becomes the base of the paraffin block to be held during sectioning by microtome.
      NOTE: This block can be stored at room temperature for further use. At this point, the process can be stopped and continued later (if required).
  5. Sectioning
    1. Install a disposable microtome blade in the blade holder. Remove excess paraffin wax around cassettes so that both the upper and lower portions of the blocks remain parallel to the knife. Fit the block on to cassette holder.
    2. Unlock the hand-wheel to advance it until the surface of the block is in contact with the edge of the knife. Trim the excess paraffin wax on the block until the tissue is visualized on the surface of the block. Set the section thickness to 5 µm and cut a ribbon of five to six sections.
    3. Using forceps, gently transfer the ribbon onto the surface of the pre-warmed water bath (around 50 °C) to unfold the ribbon. Collect sections on a glass slide coated with Mayer's albumin by holding the slide beneath the section. Gently lift the sections and allow the slides to dry horizontally overnight at 37 °C.
      ​NOTE: Slides can be stored at room temperature in dry boxes for several months. At this step, the process can be stopped and continued later.
  6. Staining
    1. Heat the slides to be stained in a hot air oven at 60 °C for 1 h before use for the paraffin to melt, and follow the steps as mentioned in Table 1.
      CAUTION: Hematoxylin and Eosin stains are toxic when inhaled or ingested. They have been reported to be carcinogenic.
ReagentStanding TimeRepetition (Number of times)
Xylene5 min2
100% Ethanol5 min2
90% Ethanol5 min2
70% Ethanol5 min2
50% Ethanol5 min2
Water5 min2
Hematoxylin4 min1
Water wash
1% Acid alcohol in 70% Ethanol30 s1
Water wash
Scott's water1 min1
Water wash
50% Ethanol1 min1
95% Ethanol1 min1
0.25% Eosin5 s1
Water wash
Water2 min1
95% Ethanol1 min1
100% Ethanol1 min1
Xylene5 min2
Mountant and coverslip

Table 1. Hematoxylin and Eosin staining procedure

2. Blood-brain barrier breakdown assay

  1. Blood and vitreous collection
    1. Anesthetize a 2 to 3-month-old diabetic Wistar male rat along with the age-matched control (14 to 15 weeks) using ketamine (80 mg/kg) and xylazine (8 mg/kg). Confirm the anesthetic state by pedal withdraw reflex (toe pinch). Immediately collect 1 mL of blood by cardiac puncture into an ethylenediaminetetraacetic acid (EDTA) coated tube to separate plasma from whole blood.
    2. Euthanize the rat using a high dose of pentobarbital (150 mg/kg), injected through the intraperitoneal route. No detectable heartbeat confirms the death within 2-5 min. Enucleate the eye and immediately place it on dry ice.
    3. Place the eye in a clean Petri dish above dry ice (recommended) and start dissecting the eye as mentioned in step 1.2.2.
    4. Remove the lens, pull the vitreous carefully from the posterior cup using micro forceps and place it in a homogenization tube containing three to four glass beads (2-4 mm).
      ​NOTE: Dissection on dry ice is recommended as removing the lens and vitreous is easier under freezing conditions.
  2. Preparation of samples
    1. Homogenize vitreous humor in a bead homogenizer at medium speed for 10 s.
    2. Transfer the blood (1 mL) and vitreous samples (10-20 µL) into the microcentrifuge tubes and centrifuge both the samples at 5200 x g for 10 min at 4 °C.
      ​NOTE: In the case of successful homogenization, vitreous has uniform consistency after centrifugation. However, in the case of non-uniform consistency of vitreous, repeat from step 2.2.1 with increased homogenization time.
    3. Collect supernatant from both samples, and dilute vitreous humor and plasma samples in 1:10 and 1:20 ratio, respectively, with PBS.
  3. Protein quantification and vitreous-plasma protein ratio
    1. To quantitate protein concentration in vitreous humor and plasma samples, add 5 µL of diluted samples to 250 µL of Bradford reagent, mix well, and read the absorbance at 590 nm within 40 min.
      NOTE: If the absorption value of the samples is above 1.0, dilute the samples further and repeat the procedure from step 2.2.3.
    2. Normalize the vitreous protein level to plasma protein level from the same rat and measure the fold difference between healthy vs. diabetic rats.

3. Fluorescence angiography

  1. FITC-dextran70000 dye injection
    1. Anesthetize a 2 to 3-month-old diabetic Wistar male rat along with the age-matched control (14 to 15 weeks) using 3% isoflurane and confirm the pedal withdrawal reflex (toe pinch). Dip the tail in a beaker containing warm water (37-40 °C). Clean the tail with 70% ethanol before injecting the dye. Locate the tail's lateral vein and mark the injection position in the lower portion of the tail.
      NOTE: If the insertion of the needle fails, try to insert in another location above the current position (tip to the base of tail). However, it is advised to inject once as repeated pricking may lead to stress development in the rat, which could cause vasoconstriction.
    2. Inject 1 mL of 50 mg/mL FITC-dextran70000 dye solution through the tail vein and allow the dye to circulate for 5 min. Euthanize the rat with a high dose of pentobarbital (150mg/kg), injected through the intraperitoneal route. No detectable heartbeat confirms the death within 2-5 min. Enucleate the eye as mentioned in step 1.1.1.
      NOTE: If required, the eye can be fixed in 4% formaldehyde solution, for no more than 30 min.
  2. Flat mount preparation
    1. For preparing flat mounts, keep the dissecting tools ready along with the slides and coverslips. Place the eye in a Petri dish filled with chilled PBS and start dissecting the eye as mentioned in step 1.2.2.
    2. Now place the tip of a pointed forcep between the sclera and retina. Gently move it all along the rim of the cup, making sure the retina is not attached to the sclera at any point. If there is any obstruction, slowly cut that portion along the rim using curved micro scissors.
    3. Once it is confirmed that the retina is not attached to the sclera from any side, cut near the optic disc, making a small hole such that the retina completely detaches from the sclera. Slowly push the retina into PBS solution and place it on a clean flat slide with the help of a spatula or forceps.
    4. Using micro scissors or scalpel blades, make minor cuts in the retinal tissue, dividing it into four quadrants. Make sure that the cuts are at least 2 mm away from the hole left by the optic disc at the center, as shown in Figure 1.
    5. Remove excess PBS from the sides of tissue using 0.2 mL tips without disturbing the flat mount.
    6. Place a drop of anti-fading mounting medium (50 µL to 100 µL) on a flat mount, cover with a coverslip, and visualize immediately under a confocal microscope.
      NOTE: Maintain minimum light during the entire procedure.
  3. Visualization of flat mount
    1. Visualize the flat mount under 10x objective of a confocal microscope. Perform tile scanning to capture the entire flat mount as a single image. The number of tiles depends upon the size of the retinal flat mount. Also, perform Z-stacking to visualize the veins and arteries in different foci (preferred size for Z-stack is 5 µm, depending on which, the number of Z-stack steps varies).
    2. Use PMT and HyD detector at % gain as 700-900 and 100-150, respectively. Choose emission range between 510-530 nm for FITC-dextran dye.

Access restricted. Please log in or start a trial to view this content.

Results

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Retinal histology
In the diabetic retina, retinal cells undergo degeneration. In addition, the thickness of the retinal layers increase due to edema22. The images obtained after Hematoxylin and Eosin staining can be used for cell count and measurement of the thickness of different layers, as shown in Figure 2 using ImageJ.

Blood-retinal barrier breakdown assay
As the BRB is compromised in diabetic r...

Access restricted. Please log in or start a trial to view this content.

Discussion

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Histology
Retinal histology is performed to visualize the morphological changes of retinal cells and layers. Various steps, including choice of fixative solution, fixation duration, dehydration, and paraffin impregnation, need to be optimized. The tissue size should not exceed 3 mm, as the fixative penetration becomes slow. The commonly used 4% paraformaldehyde leads to retinal detachment even in the healthy eye due to the relatively high osmolarity of the solution compared to aqueous humor and vit...

Access restricted. Please log in or start a trial to view this content.

Disclosures

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors declare that they have no competing financial interests.

Acknowledgements

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Authors would like to acknowledge Indian Council of Medical Research (ICMR; ITR-2020-2882) for funding support to Dr. Nirmal J. We would also like to thank University Grant of Commission for providing Junior Research Fellowship to Manisha Malani and Central Analytical Laboratory Facility, BITS-Pilani, Hyderabad campus for providing infrastructural facility.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Histology
Reagents
IsofluraneAbbottAnesthesia agent
Ketamine hydrochlorideTroikaa PharmaceuticalsAnesthesia agent
XylazineIndian Immunologicals LimitedAnesthesia agent
Pentobarbital sodiumZora PharmaEuthanesia agent
Fixative solution (1 % formaldehyde, 1.25 % GlutaraldehydeHiMedia, AvraMB059, ASG2529Prepared in-house
EthanolHaymanF204325Dehydration
XyleneHiMediaMB-180Clearing of ethanol or paraffin
Paraffin waxHiMediaGRM10702used for embedding tissue
GlycerolHiMediaTC503To prepare albumin coated slides. Glycerol and egg albumin is mixed in 1:1 ratio to coat on slides
Hydrochloric acidSisco Research laboratories Pvt. Ltd.65955For preparation of 1 % acid alcohol
Acetic acidHiMediaAS119For preparation of eosin
Scotts waterLeica3802900Bluing reagent
Papanicolaou's solution 1b Hematoxylin solutionSigma1.09254.0500Staining of nuclei
EosinHiMediaGRM115Staining of cytoplasm, 0.25 % solution was prepared in-house
DPX Mountant mediaSigma6522Visualization and protection of retinal sections
Equipments
GlasswareBorosil
Corneal forcepStephens InstrumentsS5-1200Dissection
Colibri forcepStephens InstrumentsS5-1135Dissection
Curved micro scissorStephens InstrumentsS7-1311Dissection
Vannas scissorStephens InstrumentsS7-1387Dissection
Iris scissorStephens InstrumentsS7-1015Dissection
CassettesHiMediaPW1292To hold tissue during histology processing
Water bathGT SonicGT Sonic-D9Temperature maintenance
Paraffin embedding stationMyrEC 350Preparation of paraffin blocks
MicrotomeZhengzhou Nanbei Instrument Equipment Co., Ltd.YD-335ASectioning
BladesLeicaLeica 818Sectioning
SlidesHiMediaBG005Holding paraffin-tissue sections
CoverslipsHiMediaBG014CTo cover tissue after adding mounting media
Blood Retinal Barrier breakdown
Reagents
IsofluraneAbbottB506Anesthesia
Dry iceNot applicableNot applicableDissection
Bradford reagentSigmaB6916Protein quantification
Equipments
Corneal forcepStephens InstrumentsS5-1200Dissection
Colibri forcepStephens InstrumentsS5-1135Dissection
Curved micro scissorStephens InstrumentsS7-1311Dissection
Vannas scissorStephens InstrumentsS7-1387Dissection
Iris scissorStephens InstrumentsS7-1015Dissection
GlasswareBorosilNot applicable
EDTA coated tubesJ.K DiagnosticsNot applicableSeparate plasma from whole blood
Homogenization tubesMP BiomedicalsSKU: 115076200-CFHomogenization of vitreous
Homogenization capsMP BiomedicalsSKU: 115063002-CFHomogenization of vitreous
Glass beadsMP BiomedicalsSKU: 116914801Homogenization of vitreous
HomogeniserBertin InstrumentsP000673-MLYS0-AHomogenization of vitreous
96-well plate - TransparentGrenierGN655101Protein quantification
Plate readerMolecular devicesSpectrMax M4Absorbance measurement
CentrifugeREMICPR240 PlusCentrifugation
Fluorescence Angiography
Reagents
IsofluraneAbbottB506Anesthesia
FITC-dextran 70 kD (FITC, Dextran, Dibutylin dilaurate, DMSOFITC, Dextran and Dibutylin dilaurate from Sigma; DMSO from HiMediaFITC-F3651,Dextran-31390,Dibutylin dilaurate -29123, DMSO-TC185Prepared in-house
FluoroshiedSigmaF6182Anti-fading mounting medium
Equipments
Corneal forcepStephens InstrumentsS5-1200Dissection
Colibri forcepStephens InstrumentsS5-1135Dissection
Curved micro scissorStephens InstrumentsS7-1311Dissection
Vannas scissorStephens InstrumentsS7-1387Dissection
Iris scissorStephens InstrumentsS7-1015Dissection
GlasswareBorosilNot applicable
SlidesHiMediaBG005Flatmount preparation
CoverslipsHiMediaBG014CTo cover tissue after adding mounting media
Confocal microscopeLeicaDMi8Visualization of flatmount

References

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Jonas, J. B., Sabanayagam, C. Epidemiology and risk factors for diabetic retinopathy. Diabetic Retinopathy and Cardiovascular Disease. 27, 20-37 (2019).
  2. Pandova, M. G. Visual Impairment and Blindness. , IntechOpen. (2019).
  3. Mokdad, A. H., et al. Global, regional, national, and subnational big data to inform health equity research: perspectives from the Global Burden of Disease Study 2017. Ethnicity & Disease. 29, Suppl 1 159-172 (2019).
  4. Barber, A. J., et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. The Journal of Clinical Investigation. 102 (4), 783-791 (1998).
  5. El-Asrar, A. M. A., Dralands, L., Missotten, L., Al-Jadaan, I. A., Geboes, K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Investigative Ophthalmology & Visual Science. 45 (8), 2760-2766 (2004).
  6. Schröder, S., Palinski, W., Schmid-Schönbein, G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. The American Journal of Pathology. 139 (1), 81(1991).
  7. Miyamoto, K., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences. 96 (19), 10836-10841 (1999).
  8. Bhanushali, D., et al. Linking retinal microvasculature features with severity of diabetic retinopathy using optical coherence tomography angiography. Investigative Ophthalmology & Visual Science. 57 (9), 519-525 (2016).
  9. Wang, W., Lo, A. C. Diabetic retinopathy: pathophysiology and treatments. International Journal of Molecular Sciences. 19 (6), 1816(2018).
  10. Akbarzadeh, A., et al. Induction of diabetes by streptozotocin in rats. Indian Journal of Clinical Biochemistry. 22 (2), 60-64 (2007).
  11. Weiss, R. B. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treatment Reports. 66 (3), 427-438 (1982).
  12. Karunanayake, E. H., Hearse, D. J., Mellows, G. The metabolic fate and elimination of streptozotocin. Biochemical Society Transactions. 3 (3), 410-414 (1975).
  13. Luna, L. G. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. , McGraw-Hill, Blakiston Division. New York. (1968).
  14. Okunlola, A., et al. Histological studies on the retina and cerebellum of Wistar rats treated with Arteether. Journal of Morphological Sciences. 31 (01), 028-032 (2014).
  15. Wallow, I., Engerman, R. Permeability and patency of retinal blood vessels in experimental diabetes. Investigative Ophthalmology & Visual Science. 16 (5), 447-461 (1977).
  16. do Cartmo, A., Ramos, P., Reis, A., Proença, R., Cunha-Vaz, J. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Experimental Eye Research. 67 (5), 569-575 (1998).
  17. Shires, T., Faeth, J., Pulido, J. Protein levels in the vitreous of rats with streptozotocin-induced diabetes mellitus. Brain Research Bulletin. 30 (1-2), 85-90 (1993).
  18. D'amato, R., Wesolowski, E., Smith, L. H. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvascular Research. 46 (2), 135-142 (1993).
  19. Gupta, D. Fluorescein angiography refresher course: Here's how to interpret the findings of this useful diagnostic tool. Review of Optometry. 138 (11), 60-65 (2001).
  20. Edelman, J. L., Castro, M. R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Experimental Eye Research. 71 (5), 523-533 (2000).
  21. Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. , Available from: http://monographs.iarc.fr/ENG/Monographs/vol88/index.php (2009).
  22. Szabó, K., et al. Histological evaluation of diabetic neurodegeneration in the retina of Zucker diabetic fatty (ZDF) rats. Scientific Reports. 7 (1), 1-17 (2017).
  23. Margo, C. E., Lee, A. Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefe's Archive for Clinical and Experimental Ophthalmology. 233 (6), 366-370 (1995).
  24. Tokuda, K., et al. Optimization of fixative solution for retinal morphology: a comparison with Davidson's fixative and other fixation solutions. Japanese Journal of Ophthalmology. 62 (4), 481-490 (2018).
  25. Luna, L. G. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. Third edition. , Blakiston Division, McGraw-Hill. McGraw-Hill, New York. (1968).
  26. Skeie, J. M., Tsang, S. H., Mahajan, V. B. Evisceration of mouse vitreous and retina for proteomic analyses. Journal of Visualized Experiments. (50), e2795(2011).
  27. D'Amato, R., Wesolowski, E., Smith, L. E. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvascular Research. 46 (2), 135-142 (1993).
  28. Atkinson, E. G., Jones, S., Ellis, B. A., Dumonde, D. C., Graham, E. Molecular size of retinal vascular leakage determined by FITC-dextran angiography in patients with posterior uveitis. Eye (Lond). 5, Pt 4 440-446 (1991).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Diabetic RetinopathyRetinal PathophysiologyRat ModelBlood Retinal BarrierRetinal HistologyFluorescence AngiographyRetinal Cell CountRetinal Flat MountProtein Leakage AssayRetinal Angiogenesis

Related Articles